Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
$1.1B
3.85
0.742
13
$412.8M
$435.7M
+150.0%
1.60
26.56
0.2%
524
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($63.49, 13 analysts) | |||
| 10 | $285.20 | +$349.70 (123%) | 8.2R |
| 50 | $1,426.00 | +$1,748.50 (123%) | 8.2R |
| 100 | $2,852.00 | +$3,497.00 (123%) | 8.2R |
- Elevated short interest (26.56 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| IDYA | 0.434 |
| HQH | 0.422 |
| ARKG | 0.422 |
| NRIX | 0.412 |
| IMNM | 0.407 |
| Ticker | Correlation |
|---|---|
| ESTERAD.BH | -0.161 |
| LIANY | -0.140 |
| TIOG | -0.138 |
| 006400.KS | -0.110 |
| 4002.SR | -0.110 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.